Eyepoint Pharmaceuticals Inc (EYPT)

$17.5

-3.44

(-16.43%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Eyepoint Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 15.20M → 14.02M (in $), with an average decrease of 7.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -12.61M → -14.09M (in $), with an average decrease of 11.8% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 121.6%

Performance

  • $17.12
    $20.14
    $17.50
    downward going graph

    2.2%

    Downside

    Day's Volatility :15.0%

    Upside

    13.09%

    downward going graph
  • $4.73
    $30.99
    $17.50
    downward going graph

    72.97%

    Downside

    52 Weeks Volatility :84.74%

    Upside

    43.53%

    downward going graph

Returns

PeriodEyepoint Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-8.4%
-0.7%
0.0%
6 Months
174.08%
6.6%
0.0%
1 Year
325.61%
3.7%
-1.5%
3 Years
130.62%
14.0%
-21.8%

Highlights

Market Capitalization
1.1B
Book Value
$5.43
Earnings Per Share (EPS)
-1.82
Wall Street Target Price
43.67
Profit Margin
-153.84%
Operating Margin TTM
-108.03%
Return On Assets TTM
-17.24%
Return On Equity TTM
-39.04%
Revenue TTM
46.0M
Revenue Per Share TTM
1.18
Quarterly Revenue Growth YOY
33.2%
Gross Profit TTM
26.9M
EBITDA
-73.4M
Diluted Eps TTM
-1.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.94
EPS Estimate Next Year
-2.53
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.44

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Eyepoint Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 149.54%

Current $17.50
Target $43.67

Company Financials

FY18Y/Y Change
Revenue
3.0M
↓ 60.72%
Net Income
-53.2M
↑ 187.64%
Net Profit Margin
-1.8K%
↓ 1550.52%
FY19Y/Y Change
Revenue
20.4M
↑ 587.77%
Net Income
-63.0M
↑ 18.43%
Net Profit Margin
-309.2%
↑ 1486.51%
FY20Y/Y Change
Revenue
34.4M
↑ 69.1%
Net Income
-52.7M
↓ 16.39%
Net Profit Margin
-152.89%
↑ 156.31%
FY21Y/Y Change
Revenue
36.9M
↑ 7.27%
Net Income
-63.9M
↑ 21.39%
Net Profit Margin
-173.03%
↓ 20.14%
FY22Y/Y Change
Revenue
41.4M
↑ 12.09%
Net Income
-124.5M
↑ 94.81%
Net Profit Margin
-300.72%
↓ 127.69%
FY23Y/Y Change
Revenue
46.0M
↑ 11.14%
Net Income
-70.8M
↓ 43.14%
Net Profit Margin
-153.84%
↑ 146.88%
Q3 FY22Q/Q Change
Revenue
10.0M
↓ 13.43%
Net Income
-18.4M
↓ 5.89%
Net Profit Margin
-184.2%
↓ 14.76%
Q4 FY22Q/Q Change
Revenue
10.5M
↑ 5.2%
Net Income
-64.2M
↑ 247.85%
Net Profit Margin
-609.05%
↓ 424.85%
Q1 FY23Q/Q Change
Revenue
7.7M
↓ 27.06%
Net Income
-21.6M
↓ 66.35%
Net Profit Margin
-280.96%
↑ 328.09%
Q2 FY23Q/Q Change
Revenue
9.1M
↑ 18.51%
Net Income
-22.9M
↑ 6.18%
Net Profit Margin
-251.73%
↑ 29.23%
Q3 FY23Q/Q Change
Revenue
15.2M
↑ 66.96%
Net Income
-12.6M
↓ 44.97%
Net Profit Margin
-82.96%
↑ 168.77%
Q4 FY23Q/Q Change
Revenue
14.0M
↓ 7.72%
Net Income
-14.1M
↑ 11.79%
Net Profit Margin
-100.51%
↓ 17.55%
FY18Y/Y Change
Total Assets
71.7M
↑ 283.73%
Total Liabilities
60.0M
↑ 1023.07%
FY19Y/Y Change
Total Assets
73.3M
↑ 2.31%
Total Liabilities
65.0M
↑ 8.35%
FY20Y/Y Change
Total Assets
91.7M
↑ 25.09%
Total Liabilities
73.2M
↑ 12.59%
FY21Y/Y Change
Total Assets
263.4M
↑ 187.16%
Total Liabilities
79.0M
↑ 7.95%
FY22Y/Y Change
Total Assets
180.4M
↓ 31.52%
Total Liabilities
84.0M
↑ 6.32%
FY23Y/Y Change
Total Assets
355.2M
↑ 96.93%
Total Liabilities
88.9M
↑ 5.8%
Q3 FY22Q/Q Change
Total Assets
220.5M
↓ 5.54%
Total Liabilities
84.1M
↑ 2.53%
Q4 FY22Q/Q Change
Total Assets
180.4M
↓ 18.2%
Total Liabilities
84.0M
↓ 0.18%
Q1 FY23Q/Q Change
Total Assets
154.6M
↓ 14.28%
Total Liabilities
76.2M
↓ 9.27%
Q2 FY23Q/Q Change
Total Assets
175.7M
↑ 13.62%
Total Liabilities
118.4M
↑ 55.37%
Q3 FY23Q/Q Change
Total Assets
160.0M
↓ 8.89%
Total Liabilities
101.4M
↓ 14.33%
Q4 FY23Q/Q Change
Total Assets
355.2M
↑ 121.93%
Total Liabilities
88.9M
↓ 12.38%
FY18Y/Y Change
Operating Cash Flow
-21.9M
↑ 6.92%
Investing Cash Flow
-17.0M
↑ 0.4%
Financing Cash Flow
60.7M
↑ 613.52%
FY19Y/Y Change
Operating Cash Flow
-56.7M
↑ 158.82%
Investing Cash Flow
-213.0K
↓ 98.74%
Financing Cash Flow
33.9M
↓ 44.18%
FY20Y/Y Change
Operating Cash Flow
-14.4M
↓ 74.54%
Investing Cash Flow
-362.0K
↑ 69.95%
Financing Cash Flow
37.5M
↑ 10.71%
FY21Y/Y Change
Operating Cash Flow
-50.1M
↑ 247.05%
Investing Cash Flow
-33.1M
↑ 9049.45%
Financing Cash Flow
216.9M
↑ 478.53%
FY22Y/Y Change
Operating Cash Flow
-65.0M
↑ 29.76%
Investing Cash Flow
-17.3M
↓ 47.87%
Financing Cash Flow
-690.0K
↓ 100.32%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.1M
↓ 31.31%
Investing Cash Flow
6.3M
↓ 52366.67%
Financing Cash Flow
92.0K
↓ 133.33%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.6M
↓ 4.17%
Investing Cash Flow
32.9M
↑ 424.82%
Financing Cash Flow
-58.0K
↓ 163.04%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.8M
↑ 33.74%
Investing Cash Flow
32.1M
↓ 2.52%
Financing Cash Flow
-5.1M
↑ 8725.86%
Q2 FY23Q/Q Change
Operating Cash Flow
57.0M
↓ 438.72%
Investing Cash Flow
13.5M
↓ 58.03%
Financing Cash Flow
-36.7M
↑ 616.12%

Technicals Summary

Sell

Neutral

Buy

Eyepoint Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc
-1.69%
174.08%
325.61%
130.62%
43.42%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc
NA
NA
NA
-1.94
-0.39
-0.17
NA
5.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc
Buy
$1.1B
43.42%
NA
-153.84%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Cormorant Asset Management, LLC

    12.12%

  • Franklin Resources Inc

    9.31%

  • Adage Capital Partners Gp LLC

    8.96%

  • Suvretta Capital Management, LLC

    8.14%

  • T. Rowe Price Associates, Inc.

    5.06%

  • Essex Woodlands Health Ventures

    4.69%

Corporate Announcements

  • Eyepoint Pharmaceuticals Inc Earnings

    Eyepoint Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®

Organization
Eyepoint Pharmaceuticals Inc
Employees
121
CEO
Dr. Jay S. Duker M.D.
Industry
Health Technology

Discover More

FAQs